肥満の再定義:診断の進化,治療戦略,心理社会的決定因子の物語的レビュー
Artur Przybyłowski1, Michał Górski2, Weronika Gwioździk3
1Department of Human Nutrition, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.
Healthcare (Basel, Switzerland)
|August 28, 2025
まとめ
肥満は複雑で慢性的な病気で 個別的なケアが必要です このレビューは新しい診断ツールや治療法や より良い肥満管理のために 汚名や不平等に対処することの重要性を取り上げています
科学分野:
- 内分泌学
- 公衆衛生
- 行動医学
背景:
- 肥満は慢性的で再発性 多因性疾患として認識されています
- 肥満を効果的に管理するには 個別的なケアが不可欠です
- 最近の進歩により 肥満の複雑さを理解することが 求められています
研究 の 目的:
- 肥満の定義,診断,治療における最近の進展をまとめます.
- 診断の枠組みと薬剤療法における変化を強調する.
- 介護における心理社会的要因と不平等の役割を強調する.
主な方法:
- 肥満に関する最新の文献の解説
- 診断基準に関する情報の統合 (例えば,ICD-11).
- 薬剤療法における進歩と心理社会的側面の分析
主要な成果:
- 肥満の診断と管理の枠組みは進化しています
- 肥満の薬学的な治療は 大きく進歩しました
- 心理社会的な要因や 汚名や 構造的な不平等が 介護の取り組みや 結果に影響します
結論:
- 臨床的,心理的,社会的要因を統合した多次元的なアプローチが不可欠です.
- 有効な肥満の治療には 汚名や公平性に基づいた戦略が不可欠です
- この慢性疾患の管理には 個別的で包括的なケアが不可欠です
関連する概念動画
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Bulimia Nervosa
Bulimia nervosa is a complex and severe eating disorder characterized by a cyclical pattern of binge-and-purge eating pattern. It generally involves an episode of binge eating, followed by compensatory behaviors such as vomiting, excessive exercise, laxative use, or fasting, to prevent weight gain. Despite often maintaining a normal weight, individuals with bulimia are intensely preoccupied with their body image and harbor an overwhelming fear of gaining weight. This can contribute to the...
Binge Eating Disorders
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...


